(0.04%) 5 297.50 points
(-0.09%) 38 756 points
(0.25%) 18 638 points
(0.25%) $77.18
(4.06%) $2.69
(0.01%) $2 346.10
(-0.26%) $30.36
(-0.45%) $1 037.30
(0.15%) $0.923
(0.07%) $10.49
(0.20%) $0.787
(-1.06%) $89.47
Live Chart Being Loaded With Signals
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform...
Stats | |
---|---|
今日成交量 | 192.00 |
平均成交量 | 0.00 |
市值 | 4.03M |
EPS | $-0.317 ( 2023-09-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-22 | Mckee Kelly T. Jr. | Buy | 6 944 | Common Stock |
2023-09-25 | Mckee Kelly T. Jr. | Buy | 9 653 | Common Stock |
2023-08-25 | Dodd David A | Buy | 35 087 | Common Stock |
2023-08-18 | Reynolds Mark | Buy | 10 000 | Common Stock |
2023-08-01 | Spencer John N Jr | Buy | 50 000 | Stock Option |
INSIDER POWER |
---|
99.86 |
Last 95 transactions |
Buy: 15 412 165 | Sell: 50 000 |
GeoVax Labs, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
GeoVax Labs, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-74 169.00 (0.00 %) |
EPS: | $-14.29 |
FY | 2023 |
营收: | $0 |
毛利润: | $-74 169.00 (0.00 %) |
EPS: | $-14.29 |
FY | 2022 |
营收: | $81 000.00 |
毛利润: | $24 716.00 (30.51 %) |
EPS: | $-12.39 |
FY | 2021 |
营收: | $385 501 |
毛利润: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。